OMEGA THERAPEUTICS, INC.

EPIGENOMIC PROGRAMMING

scientific research; pharmaceutical research services; medical research; technical scientific consulting services in the field of biotechnology; product development for others in the field of biotechnology; development of pharmaceutical preparations and medicines;

EPIGENOMIC PROGRAMMING

Pharmaceutical agents affecting DNA structure and/or epigenomic state by targeting DNA structure to treat various diseases; Pharmaceutical agents affecting DNA structure and/or epigenomic state by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease, CNS disorders;

GENOMSTAT

Pharmaceutical agents affecting DNA structure by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease, multigenic disorders, hepatic disorders and disorders of the CNS, none of the foregoing including omega fatty acids;

MYCHELANGELO

Pharmaceutical agents and molecules; pharmaceutical agents affecting DNA structure by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease; scientific research; pharmaceutical research services; medical research; technical scientific consulting services in the field of biotechnology; product development for others in the field of biotechnology; development of pharmaceutical preparations and medicines; research and development in the field of computational biology, bioinformatics, biotechnology and pharmaceuticals; therapeutics containing MYC inhibiting properties;

NATIVE GENE CONTROL

Pharmaceutical agents that target DNA structure to treat various diseases, namely, monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease;GENE CONTROL;

NATIVE GENE CONTROL

Pharmaceutical agents that target DNA structure to treat various diseases, namely, monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease;GENE CONTROL;

NATIVE GENE THERAPY

Pharmaceutical agents that target DNA structure to treat various diseases, namely, monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease;GENE THERAPY;

NATIVE GENE THERAPY

Pharmaceutical agents that target DNA structure to treat various diseases, namely, monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease;GENE THERAPY;

NGEN

Research and development in the field of computational biology, bioinformatics, biotechnology and pharmaceuticals; none of the foregoing relating to human growth hormones, mutation detection reagents, genome editing reagents, polynucleotide assembly reagents, or endocrine diseases and disorders;

NGEN-OS

Research and development in the field of computational biology, bioinformatics, biotechnology and pharmaceuticals; none of the foregoing relating to human growth hormones, mutation detection reagents, genome editing reagents, polynucleotide assembly reagents, or endocrine diseases and disorders;

OEC

Pharmaceutical agents affecting DNA structure by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease, none of the foregoing including omega fatty acids;

OMEGA

The mark consists of an incomplete circle superimposed over an incomplete triangle with the circle and triangle joined at the bottom to the left of the word OMEGA in a stylized font.;Color is not claimed as a feature of the mark.;scientific research; pharmaceutical research services; medical research; technical scientific consulting services in the field of biotechnology; Product development for others in the field of biotechnology; Development of pharmaceutical preparations and medicines;